Local pharmaceutical firm enters partnership valued up to $493M

A Celebration-based pharmaceutical company could end up with an extremely large investment if its product candidates for ADHD treatment are approved.

KemPharm Inc. (Nasdaq: KMPH) entered a licensing agreement with Cambridge, Massachusetts-based Gurnet Point Capital LLC on up to $493 million in upfront, sales and development milestone payments. The company will receive $10 million upfront, and could receive pre-approval cost reimbursements, regulatory milestone payments as well as sales milestone payments valued up to $483 million and separate sales royalties as part of the deal. Read more here.